Selected work, anonymised. Program detail and partner identities are available to qualified parties under NDA.
Selected programs across complex injectable platforms. Open a case for the challenge, approach and outcome. Program-level detail is available to qualified partners under NDA.
Most of the products we have developed address actives that are poorly soluble or insoluble in water.
Two injectable emulsion presentations, each reformulated without organic solvent.
Read caseDevelop solvent-free versions of two established injectable emulsion presentations of an antiemetic.
Emulsion formulations designed to dispense with solvent while remaining physically stable and suitable for injection.
Solvent-free formulations developed for both emulsion presentations.
Off Targets R&D led formulation development.
A differentiated injectable emulsion for acute cardiovascular care.
Read caseCreate a differentiated version of an established acute-care emulsion, with a composition that stands apart from the reference while serving the same clinical purpose.
A reformulated emulsion composition that differs from the reference while serving the same clinical purpose.
Differentiated formulation developed.
Off Targets R&D led formulation development.
A nanosuspension of a water-insoluble active for injection.
Read caseDeliver a water-insoluble active as an injectable suspension at a concentration that solution formulations cannot reach.
Particle-size engineering to produce a nanometre-scale suspension of the active.
Nanosuspension formulation developed.
Off Targets R&D led formulation development.
Generic equivalents of two established lipid emulsions, including a fish-oil-derived product.
Read caseMatch the composition and physical characteristics of two established lipid emulsions used in parenteral nutrition.
Formulations developed to match the references qualitatively and quantitatively, supported by characterisation of globule size and emulsion stability.
Formulations developed.
Off Targets R&D led formulation development.
Three long-acting programs, including a differentiated alternative to a leading product.
Read caseDevelop long-acting injectable versions of three established antipsychotics, including a differentiated alternative to a leading long-acting product.
Sustained-release depot formulations engineered for controlled release across the dosing interval.
Three long-acting formulations developed.
Off Targets R&D led formulation development.
A differentiated extended-release combination of a local anaesthetic and an anti-inflammatory.
Read caseDeliver two actives with very different properties from a single extended-release depot for post-operative pain.
A differentiated depot formulation that co-delivers both actives.
Differentiated formulation developed.
Off Targets R&D led formulation development.
A cytotoxic reformulated to remove the excipient associated with hypersensitivity reactions.
Read caseThe active is poorly soluble in water, and the established product relies on a solubilising excipient associated with hypersensitivity reactions and the need for premedication.
A lipid-based nanoparticle formulation designed to carry the active without that excipient.
Formulation developed that removes the excipient by design. Clinical benefit remains to be established.
Off Targets R&D led formulation development.
Descriptions are anonymised. “Developed” refers to formulation development and does not imply regulatory approval.
The structures below have each been used in practice. Partner identities and terms are confidential.
Co-development, territory-split licensing and strategic portfolio development, each with a different type of partner.
Joint development with an active-ingredient manufacturer.
Read caseA program where the API source and the formulation expertise sat with different parties.
Co-development with the API manufacturer as partner, combining its API capability with our formulation development.
Structure operated in practice. Program detail and terms are confidential and available to qualified partners under NDA.
API partner: active ingredient. Off Targets: formulation development.
Joint development with a contract manufacturer.
Read caseA program where manufacturing capability and formulation expertise sat with different parties.
Co-development with a contract manufacturer as partner, aligning formulation development with manufacturing from an early stage.
Structure operated in practice. Program detail and terms are confidential and available to qualified partners under NDA.
CMO partner: manufacturing. Off Targets: formulation development.
Joint development with a virtual pharmaceutical company.
Read caseA virtual pharmaceutical company with portfolio and market ambitions but no laboratory or formulation team of its own.
Co-development with the virtual company as partner, with Off Targets providing the technical development capability.
Structure operated in practice. Program detail and terms are confidential and available to qualified partners under NDA.
Virtual pharma partner: portfolio and commercial direction. Off Targets: development.
A licensee that went on to build a curated portfolio with us.
Read caseA company in-licensed one of our products.
The relationship extended into joint development and joint investment in a curated portfolio of products for oncology and critical care.
Structure operated in practice. Program detail and terms are confidential and available to qualified partners under NDA.
Licensee: joint investment. Off Targets: joint development.
One program licensed by territory across two regions.
Read caseA program with distinct commercial opportunities in the United States and Europe.
Licensing split by territory, so that each region could be partnered separately.
Structure operated in practice. Program detail and terms are confidential and available to qualified partners under NDA.
Licensees: commercialisation in their territory. Off Targets: development and licensing.
One program licensed by territory across two regions.
Read caseA program with distinct commercial opportunities in the United States and China.
Licensing split by territory, so that each region could be partnered separately.
Structure operated in practice. Program detail and terms are confidential and available to qualified partners under NDA.
Licensees: commercialisation in their territory. Off Targets: development and licensing.
A portfolio of products developed with a financial partner.
Read caseA set of products that justified development as a portfolio rather than program by program.
Strategic development of the portfolio in partnership with a strategic financial partner.
Structure operated in practice. Program detail and terms are confidential and available to qualified partners under NDA.
Financial partner: strategic backing. Off Targets: development.